AAAAAA

   
Results: 1-12 |
Results: 12
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3099-3102
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3103-3106
Combinatorial synthesis of CCR5 antagonists
Authors: Willoughby, CA Berk, SC Rosauer, KG Degrado, S Chapman, KT Gould, SL Springer, MS Malkowitz, L Schleif, WA Hazuda, D Miller, M Kessler, J Danzeisen, R Holmes, K Lineberger, J Carella, A Carver, G Emini, EA
Citation: Ca. Willoughby et al., Combinatorial synthesis of CCR5 antagonists, BIOORG MED, 11(24), 2001, pp. 3137-3141
1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity
Authors: Hale, JJ Budhu, RJ Holson, EB Finke, PE Oates, B Mills, SG MacCoss, M Gould, SL DeMartino, JA Springer, MS Siciliano, S Malkowitz, L Schleif, WA Hazuda, D Miller, M Kessler, J Danzeisen, R Holmes, K Lineberger, J Carella, A Carver, G Emini, E
Citation: Jj. Hale et al., 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity, BIOORG MED, 11(20), 2001, pp. 2741-2745
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
Authors: Dorn, CP Finke, PE Oates, B Budhu, RJ Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Cp. Dorn et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 259-264
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes
Authors: Finke, PE Meurer, LC Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 265-270
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes
Authors: Finke, PE Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Gould, SL DeMartino, JA Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes, BIOORG MED, 11(18), 2001, pp. 2475-2479
Reliability of C-min: Inhibitory concentration ratios - Reply
Authors: Condra, JH Petropoulos, CJ Ziermann, R Schleif, WA Shivaprakash, M Emini, EA
Citation: Jh. Condra et al., Reliability of C-min: Inhibitory concentration ratios - Reply, J INFEC DIS, 183(6), 2001, pp. 993-994
Combinatorial diversification of indinavir: In vivo mixture dosing of an HIV protease inhibitor library
Authors: Rano, TA Cheng, Y Huening, TT Zhang, FQ Schleif, WA Gabryelski, L Olsen, DB Kuo, LC Lin, JH Xu, X Olah, TV McLoughlin, DA King, R Chapman, KT Tata, JR
Citation: Ta. Rano et al., Combinatorial diversification of indinavir: In vivo mixture dosing of an HIV protease inhibitor library, BIOORG MED, 10(14), 2000, pp. 1527-1530
4-aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells
Authors: Wai, JS Egbertson, MS Payne, LS Fisher, TE Embrey, MW Tran, LO Melamed, JY Langford, HM Guare, JP Zhuang, LG Grey, VE Vacca, JP Holloway, MK Naylor-Olsen, AM Hazuda, DJ Felock, PJ Wolfe, AL Stillmock, KA Schleif, WA Gabryelski, LJ Young, SD
Citation: Js. Wai et al., 4-aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells, J MED CHEM, 43(26), 2000, pp. 4923-4926
Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors
Authors: Dorsey, BD McDonough, C McDaniel, SL Levin, RB Newton, CL Hoffman, JM Darke, PL Zugay-Murphy, JA Emini, EA Schleif, WA Olsen, DB Stahlhut, MW Rutkowski, CA Kuo, LC Lin, JH Chen, IW Michelson, SR Holloway, MK Huff, JR Vacca, JP
Citation: Bd. Dorsey et al., Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors, J MED CHEM, 43(18), 2000, pp. 3386-3399
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
Authors: Condra, JH Petropoulos, CJ Ziermann, R Schleif, WA Shivaprakash, M Emini, EA
Citation: Jh. Condra et al., Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy, J INFEC DIS, 182(3), 2000, pp. 758-765
Risultati: 1-12 |